Avidity Partners Management LP David Witzke
Dallas, TX 21 processed 13Fs on this site, 2021 Q3 to 2026 Q2
- $624M
- 45 holdings
- 2026 Q2
- +41.2% QoQ
- Top 5 70.9%
AUM over time
Book
| Mirati Therapeutics | Hold | 1,062,400 | $176.91 | $188M | |
| ARVN, Arvinas | Hold | 2,234,700 | $82.18 | $184M | |
| ABBV, AbbVie | Hold | 1,613,200 | $107.87 | $174M | |
| VRTX, Vertex Pharmaceuticals | Hold | 926,400 | $181.39 | $168M | |
| ZNTL, Zentalis Pharmaceuticals | Hold | 2,493,800 | $66.64 | $166M | |
| AVTR, Avantor | Hold | 3,247,700 | $40.90 | $133M | |
| BHVN, Biohaven | Hold | 934,200 | $138.91 | $130M | |
| SNDX, Syndax Pharmaceuticals | Hold | 4,823,400 | $19.11 | $92M | |
| REGN, Regeneron | Hold | 152,300 | $605.18 | $92M | |
| Seagen | Hold | 537,000 | $169.80 | $91M | |
| Horizon Therapeutics Pub | Hold | 826,000 | $109.54 | $90M | |
| Blueprint Medicines | Hold | 832,000 | $102.81 | $86M | |
| AZNN | Hold | 1,412,000 | $60.06 | $85M | |
| NBIX, Neurocrine Biosciences | Hold | 848,900 | $95.91 | $81M | |
| ALNY, Alnylam Pharmaceuticals | Hold | 427,000 | $188.81 | $81M | |
| LLY, Eli Lilly | Hold | 330,000 | $231.05 | $76M | |
| NUVB, Nuvation Bio | Hold | 7,263,488 | $9.94 | $72M | |
| NTRA, Natera | Hold | 638,700 | $111.44 | $71M | |
| HOLX, Hologic | Hold | 945,400 | $73.81 | $70M | |
| BAX, Baxter International | Hold | 862,000 | $80.43 | $69M | |
| Arena Pharmaceuticals | Hold | 1,139,000 | $59.55 | $68M | |
| Iveric Bio | Hold | 4,100,000 | $16.24 | $67M | |
| UTHR, United Therapeutics | Hold | 351,000 | $184.58 | $65M | |
| Stevanato Group | Hold | 2,541,893 | $25.31 | $64M | |
| SHC, Sotera Health | Hold | 2,378,000 | $26.15 | $62M | |
| IDYA, Ideaya Biosciences | Hold | 2,437,000 | $25.49 | $62M | |
| CRBU, Caribou Biosciences | Hold | 2,474,067 | $23.87 | $59M | |
| Catalent | Hold | 398,000 | $133.07 | $53M | |
| Gritstone Bio | Hold | 4,457,831 | $10.80 | $48M | |
| Legend Biotech | Hold | 894,000 | $50.56 | $45M | |
| Holding | Hold | 2,398,000 | $18.48 | $44M | |
| PFE, Pfizer | Hold | 1,026,800 | $43.01 | $44M | |
| ARWR, Arrowhead Pharmaceuticals | Hold | 673,700 | $62.43 | $42M | |
| Shattuck Labs | Hold | 2,025,000 | $20.38 | $41M | |
| RARE | Hold | 455,000 | $90.19 | $41M | |
| Immunocore | Hold | 1,095,600 | $37.07 | $41M | |
| RNA, Avidity Biosciences | Hold | 1,645,000 | $24.63 | $41M | |
| IOVA, Iovance Biotherapeutics | Hold | 1,462,200 | $24.66 | $36M | |
| INSM, Insmed | Hold | 1,292,000 | $27.54 | $36M | |
| Exact Sciences | Hold | 369,000 | $95.45 | $35M | |
| CMPS, Compass Pathways | Hold | 1,162,000 | $29.87 | $35M | |
| ATEC, Alphatec | Hold | 2,786,000 | $12.19 | $34M | |
| INTC, Intellia Therapeutics | Hold | 251,000 | $134.15 | $34M | |
| I Mab | Hold | 454,000 | $72.49 | $33M | |
| Seaspine | Hold | 1,943,000 | $15.73 | $31M | |
| Bellus Health | Hold | 4,942,000 | $6.14 | $30M | |
| KYMR, Kymera Therapeutics | Hold | 514,500 | $58.74 | $30M | |
| Cyteir Therapeutics | Hold | 1,683,441 | $17.55 | $30M | |
| ALT, Altimmune | Hold | 2,167,900 | $11.31 | $25M | |
| VIR, Vir Biotechnology | Hold | 515,000 | $43.52 | $22M | |
| Alpine Immune Sciences | Hold | 1,932,000 | $10.67 | $21M | |
| Holding | Hold | 2,450,000 | $8.00 | $20M | |
| Adicet Bio | Hold | 2,419,600 | $7.84 | $19M | |
| IPSC, Century Therapeutics | Hold | 739,269 | $25.16 | $19M | |
| SIBN, Si-Bone | Hold | 831,200 | $21.42 | $18M | |
| Sana Biotechnology | Hold | 774,644 | $22.52 | $17M | |
| PATH, Uipath | Hold | 319,000 | $52.61 | $17M | |
| TCOM, Field Trip Health | Hold | 3,581,000 | $4.59 | $16M | |
| LFST, Lifestance Health Group | Hold | 1,000,000 | $14.50 | $15M | |
| Phasebio Pharmaceuticals | Hold | 4,405,000 | $3.11 | $14M | |
| Sema4 | Hold | 1,660,000 | $7.59 | $13M | |
| GH Research | Hold | 560,000 | $22.06 | $12M | |
| Graphite Bio | Hold | 748,995 | $16.39 | $12M | |
| Ac Immune | Hold | 1,739,600 | $6.71 | $12M | |
| SCYX, Scynexis | Hold | 2,060,000 | $5.30 | $11M | |
| Werewolf Therapeutics | Hold | 625,120 | $17.16 | $11M | |
| S, Sentinelone | Hold | 200,000 | $53.57 | $11M | |
| Harpoon Therapeutics | Hold | 1,190,600 | $7.90 | $9.4M | |
| Engagesmart | Hold | 275,000 | $34.06 | $9.4M | |
| ACAD, Acadia Pharmaceuticals | Hold | 550,000 | $16.61 | $9.1M | |
| Orchard Therapeutics | Hold | 3,836,798 | $2.30 | $8.8M | |
| Caremax | Hold | 827,402 | $9.66 | $8M | |
| Zeta Global | Hold | 1,300,000 | $5.86 | $7.6M | |
| Instil Bio | Hold | 408,140 | $17.88 | $7.3M | |
| GLUE, Monte Rosa Therapeutics | Hold | 300,000 | $22.28 | $6.7M | |
| Oncosec Medical | Hold | 2,945,000 | $2.13 | $6.3M | |
| Talaris Therapeutics | Hold | 455,000 | $13.56 | $6.2M | |
| Holding | Hold | 35,000 | $172.11 | $6M | |
| Keros Therapeutics | Hold | 145,100 | $39.56 | $5.7M | |
| Ziopharm Oncology | Hold | 3,000,000 | $1.82 | $5.5M | |
| Holding | Hold | 520,000 | $9.75 | $5.1M | |
| Arya Sciences Acqu Corporation IV | Hold | 500,000 | $10.05 | $5M | |
| Bcls Acquisition | Hold | 500,000 | $9.96 | $5M | |
| Holding | Hold | 500,000 | $9.94 | $5M | |
| Healthcor Catalio Acqu | Hold | 500,000 | $9.90 | $5M | |
| Panacea Acquisition Corporation II | Hold | 500,000 | $9.77 | $4.9M | |
| Somalogic | Hold | 330,000 | $12.39 | $4.1M | |
| Health Sciences Acq Corporation 2 | Hold | 400,000 | $9.89 | $4M | |
| Helix Acquisition | Hold | 400,000 | $9.85 | $3.9M | |
| Lifesci Acquisition II | Hold | 400,000 | $9.80 | $3.9M | |
| TNGX, Tango Therapeutics | Hold | 300,000 | $12.93 | $3.9M | |
| ZLAB, Zai Lab | Hold | 35,600 | $105.39 | $3.8M | |
| Nautilus Biotechnology | Hold | 600,000 | $6.14 | $3.7M | |
| Sight Sciences | Hold | 145,189 | $22.70 | $3.3M | |
| Atai Life Sciences | Hold | 218,730 | $14.79 | $3.2M | |
| Kezar Life Sciences | Hold | 260,000 | $8.64 | $2.2M | |
| Holding | Hold | 200,000 | $9.95 | $2M | |
| Holding | Hold | 200,000 | $9.88 | $2M | |
| Social Cap Suvretta Hlds CP | Hold | 200,000 | $9.81 | $2M | |
| Holding | Hold | 200,000 | $9.80 | $2M |
Showing top 50 of 100 by value
Filings history
20 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 45 | $624M | +41.2% | 13F-HR | 8/14/2026 | 000179182726000005 |
| 2026 Q1 | 45 | $494M | — | new holds | 5/28/2026 | 000179182726000004 |
| 2026 Q1 | 46 | $442M | +27.4% | 13F-HR | 5/13/2026 | 000179182726000003 |
| 2025 Q4 | 39 | $347M | −21.0% | 13F-HR | 2/13/2026 | 000179182726000002 |
| 2025 Q3 | 43 | $439M | −12.5% | 13F-HR | 11/14/2025 | 000179182725000008 |
| 2025 Q2 | 56 | $502M | −4.4% | 13F-HR | 8/14/2025 | 000179182725000007 |
| 2025 Q1 | 67 | $525M | −48.4% | 13F-HR | 5/15/2025 | 000179182725000005 |
| 2024 Q4 | 63 | $1B | −48.1% | 13F-HR | 2/14/2025 | 000179182725000002 |
| 2024 Q3 | 81 | $2B | −16.7% | 13F-HR | 11/14/2024 | 000179182724000011 |
| 2024 Q2 | 85 | $2.4B | −24.1% | 13F-HR | 8/14/2024 | 000179182724000007 |
| 2024 Q1 | 90 | $3.1B | +13.0% | 13F-HR | 5/15/2024 | 000179182724000004 |
| 2023 Q4 | 74 | $2.7B | +10.5% | 13F-HR | 2/14/2024 | 000179182724000002 |
| 2023 Q3 | 83 | $2.5B | −13.3% | 13F-HR | 11/14/2023 | 000179182723000006 |
| 2023 Q2 | 93 | $2.9B | −5.0% | 13F-HR | 8/14/2023 | 000179182723000004 |
| 2023 Q1 | 83 | $3B | −34.7% | 13F-HR | 5/15/2023 | 000179182723000003 |
| 2022 Q4 | 85 | $4.6B | −6.2% | 13F-HR | 2/14/2023 | 000179182723000002 |
| 2022 Q3 | 97 | $4.9B | +12.9% | 13F-HR | 11/14/2022 | 000179182722000008 |
| 2022 Q2 | 82 | $4.4B | −9.3% | 13F-HR | 8/15/2022 | 000179182722000006 |
| 2022 Q1 | 92 | $4.8B | +1.9% | 13F-HR | 5/16/2022 | 000179182722000004 |
| 2021 Q4 | 97 | $4.7B | +4.5% | 13F-HR | 2/14/2022 | 000179182722000002 |
| 2021 Q3 | 105 | $4.5B | — | 13F-HR | 11/15/2021 | 000179182721000006 |
About
Avidity Partners Management LP
21 processed 13Fs on this site, 2021 Q3 to 2026 Q2
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
- One Up On Wall Street (Lynch), Peter Lynch View on Amazon